Topical vitamin-D analogues and corticosteroids

01Purpose and principlesWhat the treatment does and how it fits into care.

Vitamin-D analogues normalise keratinocyte growth while corticosteroids suppress inflammation. Their benefits are complementary, but neither class is a generic cream: exposure limits, site anatomy and treatment breaks determine safety.

A prescription is incomplete without formulation, exact site, frequency, duration, quantity and review. Failure often reflects an unacceptable vehicle, under-supply, scale blocking contact or medicine applied to hair rather than skin.

NICE sequences differ for trunk and limbs, scalp, and sensitive sites. A product licence may also differ from a guideline sequence, so record whether the regimen is licensed, guideline-supported, or specialist off-label use.

Key points

Topical treatment is first-line for most psoriasis, but the safest active ingredient, potency, formulation, frequency and duration are site-specific.
For adult trunk or limb plaques, NICE initial treatment is a potent corticosteroid once daily plus vitamin-D analogue once daily, applied separately morning and evening, for up to four weeks.
For scalp psoriasis, NICE starts a potent corticosteroid once daily for up to four weeks; check hair-parting, vehicle and scale before switching.
For face, flexures or genitals, use mild or moderate potency corticosteroid once or twice daily for no more than two weeks; do not use potent or very potent products there.
Do not use very potent corticosteroid continuously beyond four weeks or potent corticosteroid continuously beyond eight weeks at any site; repeated courses require deliberate review.
Calcipotriol 50 micrograms/g ointment is licensed once or twice daily on adult trunk or limbs with a 100 g weekly maximum; avoid calcium disorders and severe renal or hepatic impairment.
Fixed calcipotriol 50 micrograms/g plus betamethasone 0.5 mg/g ointment is licensed once daily for four weeks, maximum 15 g daily and no more than 30% body surface area.
Teach fingertip units, wash hands after application, separate emollient and active products, and warn that emollient-contaminated fabrics burn more intensely even after drying.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Suitable limited plaques

Stable, localised plaque psoriasis with a confirmed diagnosis and manageable surface area is suited to topical treatment. Measure site and extent before selecting potency and quantity.

Sensitive-site skin

Face, flexures and genitals absorb corticosteroid more readily and are vulnerable to atrophy, striae and telangiectasia. Minimal scale and occlusion do not justify higher potency.

Steroid adverse effectsRed flag

Atrophy, easy bruising, telangiectasia, striae, acneiform eruption, perioral dermatitis and rebound suggest excessive exposure; widespread or occluded use can suppress the hypothalamic-pituitary-adrenal axis.

Vitamin-D irritation

Burning, dermatitis or facial irritation may follow calcipotriol transfer. Excess dose or large-area treatment raises hypercalcaemia risk, especially with calcium-active medicines or impaired clearance.

Infection before escalationRed flag

New weeping, honey crust, pustules, grouped painful vesicles or spreading tenderness should trigger infection assessment. Corticosteroid can alter appearance and worsen untreated infection.

Topical treatment failure

Before labelling drug failure, ask the person to demonstrate application, reconcile tube size and duration, inspect the vehicle and scale, and confirm that the diagnosis and treated site remain correct.

Red flags requiring action

Widespread pustulation, erythroderma, fever, shivering or haemodynamic disturbance requires urgent specialist treatment rather than a larger topical prescription.
Progressive weakness, vomiting, constipation, confusion, polyuria or thirst during excessive calcipotriol exposure may signal hypercalcaemia and needs urgent biochemical and medication review.
Facial rounding, growth suppression in a child, extensive atrophy or symptoms of adrenal insufficiency after high-potency or occluded steroid exposure requires prompt assessment.
Painful spreading warmth, purulence, clustered blisters or erosions suggests bacterial or herpetic infection; reassess before increasing topical immunosuppression.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line site, extent and formulation assessmentFirst stepFirst line
Why
Choose corticosteroid potency, vitamin-D formulation and quantity according to anatomy and plaque characteristics.
Interpretation and limitations
Thick trunk plaques, hairy scalp and thin flexural skin need different vehicles and safety ceilings; one copied prescription is inappropriate across all three.
02
Fingertip-unit quantity calculation
Why
Ensure enough product is supplied for the prescribed area without uncontrolled excess.
Interpretation and limitations
One adult fingertip unit is approximately 0.5 g and covers about two adult handprints. Use this as teaching approximation and reconcile against product-specific maximum doses.
03
Medication and comorbidity review
Why
Identify calcium disorders, severe renal or hepatic disease, infection, pregnancy considerations and other corticosteroid exposure.
Interpretation and limitations
Calcipotriol exposure adds across ointment, cream and scalp solution; systemic calcium or vitamin-D products and thiazides can increase hypercalcaemia risk.
04
Targeted serum calcium and renal profile
Why
Assess suspected excessive calcipotriol exposure, hypercalcaemia symptoms or relevant organ impairment.
Interpretation and limitations
Routine blood testing is unnecessary for correctly dosed small-area topical treatment, but elevated calcium requires stopping excess exposure and urgent clinical interpretation.
05
Mycology or microbiology when morphology changes
Why
Avoid masking fungal, bacterial or viral infection with stronger topical corticosteroid.
Interpretation and limitations
Sample the active representative site before antimicrobial treatment when safe; a negative poor specimen should not overrule a convincing clinical pattern.

04Treatment approachPreparation, options, escalation and aftercare.

01First-lineAdult trunk and limb plaquesFirst stepFirst lineStable plaque psoriasis suitable for topical treatment away from face, flexures and genitals.

1Agree ointment, cream, gel or foam according to thickness, hair, daily routine and preference; demonstrate the exact plaques and quantity to treat.
2Apply a potent corticosteroid once daily plus vitamin-D analogue once daily at different times, morning and evening, for up to four weeks under NICE guidance.
3Review by four weeks for clearance, irritation, atrophy, amount used and adherence; if continuing a fixed combination after its licensed course, require medical review and supervision.
4Use the subsequent NICE sequence rather than continuous potent steroid, and refer when extent, impact or correct topical failure makes phototherapy or systemic treatment appropriate.

02ScalpDeliver medicine through hair and scaleScalp plaques without untreated infection or scarring alopecia.

1Part hair and use scale-softening treatment when necessary, avoiding forceful removal that causes bleeding and Koebnerisation.
2Apply a potent corticosteroid scalp formulation once daily for up to four weeks directly to skin, not chiefly to hair.
3If response is unsatisfactory, check technique and offer a different potent-steroid vehicle and/or descaling before the later NICE combination or vitamin-D branch.

03Sensitive sitesMinimise atrophy and irritationPsoriasis affecting facial, flexural or genital skin.

1Confirm psoriasis and exclude fungal, candidal or irritant disease where morphology is atypical.
2Use mild or moderate potency corticosteroid once or twice daily for no more than two weeks; never use potent or very potent products on these sites.
3When repeated treatment is needed and atrophy risk is serious, an experienced clinician may offer topical calcineurin inhibitor twice daily for up to four weeks, explaining off-label psoriasis use.

04Safety reviewPrevent cumulative toxicityRepeat courses, large quantities, occlusion, a child, or new adverse effects.

1Reconcile every topical product and strength, including combinations, borrowed tubes and non-prescription preparations; count total calcipotriol and corticosteroid exposure.
2Inspect for atrophy, striae, telangiectasia, infection and disease rebound; investigate calcium or adrenal disturbance when symptoms and exposure justify it.
3Do not use continuous very potent steroid beyond four weeks or potent steroid beyond eight weeks, and perform at least annual adverse-effect review for intermittent potent or very potent use in adults.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Licensed vitamin-D analogue monotherapy for mild to moderately severe plaque psoriasis or a separate component of the NICE trunk-and-limb sequence.

Calcipotriol 50 micrograms/g ointment

Apply thinly to affected trunk or limb skin once or twice daily; do not exceed 100 g weekly, and expect a pronounced effect over about 4 to 8 weeks.

Avoid face, calcium-metabolism disorders, severe renal or hepatic impairment and guttate, erythrodermic or pustular psoriasis under this SmPC; wash hands and total all calcipotriol products.

Licensed fixed combination for stable adult plaque psoriasis and a NICE adherence-oriented option at defined points in trunk, limb or scalp treatment sequences.

Calcipotriol 50 micrograms/g with betamethasone 0.5 mg/g ointment

Apply to affected adult plaque psoriasis once daily for 4 weeks; maximum 15 g daily and no more than 30% body surface area with calcipotriol-containing products.

Avoid face, flexures and genitals, calcium disorders, severe renal or hepatic impairment, untreated infection and unstable pustular or erythrodermic psoriasis; further courses require medical review.

Licensed potent topical corticosteroid for steroid-responsive psoriasis excluding widespread plaque disease; lotion is useful on hair-bearing skin.

Betamethasone valerate 0.1% cream or lotion

Apply a thin layer once or twice daily for up to 4 weeks until improvement, then reduce frequency or step down; formulation and quantity follow the treated site.

Do not use on untreated infection or sensitive sites without a site-appropriate plan; reassess if worse or unimproved within 2 to 4 weeks and avoid abrupt uncontrolled long-term withdrawal.

Very potent corticosteroid reserved for resistant plaques in specialist-supervised contexts after less potent treatment has failed.

Clobetasol propionate 0.05% ointment

Apply thinly once or twice daily for the shortest resistant-disease course, stepping down or stopping by 4 weeks; do not exceed 50 g in one week.

Not for widespread plaque psoriasis, face, flexures, genitals or untreated infection; occlusion and large inflamed areas magnify adrenal suppression and local atrophy.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Review a new active topical regimen by four weeks and record treated site, patient goal, quantity used, adherence, response, irritation, infection and corticosteroid adverse effects.
When calcipotriol products are combined, calculate total exposure across every formulation and keep within the relevant product maximum; test calcium only when exposure or symptoms justify it.
Inspect adults using intermittent potent or very potent corticosteroid at least annually for atrophy and other adverse effects; children using any corticosteroid require at least annual review.
Photographing response can aid comparison across skin tones, but obtain specific consent, avoid unnecessary identifying features and store images only in the approved clinical record.
Escalate to dermatology when correctly applied topical therapy cannot control disease, when high-impact sites dominate, or when repeat steroid courses are becoming the maintenance plan.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Add exposures across products

A combination ointment and a scalp solution both contribute calcipotriol. Medicine reconciliation must total the active ingredient, not count brand names as unrelated treatments.

One fingertip unit

About 0.5 g from the adult index fingertip to distal crease covers roughly two adult handprints. It is a practical approximation for teaching and supply.

Occlusion multiplies effect

Covering a corticosteroid increases penetration and adverse-event risk. Use it only as a prescribed time-limited technique, never as an improvised answer to poor response.

The tube tells a story

An almost-full tube after four weeks may mean non-use, poor access or confusion; an unexpectedly empty tube may reveal over-application or treatment of the wrong area.

Pigment lags inflammation

Lightening or darkening can persist after plaques flatten. Continuing potent steroid solely to normalise colour risks harm without treating active disease.

08Common pitfallsFrequent interpretation and management errors.

01
Writing apply as directed without site, quantity, frequency, duration or review point.
02
Using potent or very potent corticosteroid on face, flexures or genitals because the plaque looks severe.
03
Forgetting calcipotriol hidden in fixed combinations when checking the total weekly dose.
04
Calling a treatment ineffective before checking formulation, hair-parting, scale, supply and actual application.
05
Continuing topical corticosteroid to treat residual pigment rather than current thickness, scale or symptoms.
06
Ignoring fabric fire risk because an emollient or oily topical has already dried.